CJC-1295 isn't found on pharmacy shelves in Aígio or virtually any local market — this is a specialist compound available through a dedicated online market. What this means for Aígio researchers is that physical proximity is irrelevant compared to your ability to verify analytical documentation — and those evaluation tools are accessible to anyone. The core quality markers for CJC-1295 are HPLC purity ≥98%, molecular identity verified through mass spectrometry, and a bacterial endotoxin panel — all documented in a batch-matched Certificate of Analysis. What follows is a practical research guide built specifically around CJC-1295, covering everything a Aígio researcher needs before placing a first order.
What Studies Say About CJC-1295
The selectivity profile of different GHS compounds is a critical research consideration. GHRP-6 and GHRP-2 produce GH release alongside cortisol and prolactin elevation — a confounding factor in research designs where these hormones are outcome variables. Ipamorelin was specifically developed for greater GH-release selectivity with minimal cortisol and prolactin elevation, making it more suitable for research designs where GH-specific effects need to be isolated. Hexarelin has the strongest GH-releasing potency in the GHRP class but also the most significant cortisol and prolactin effects. For Aígio researchers designing GH-axis studies, compound selection based on this selectivity profile should precede protocol finalization.
Buying CJC-1295: Quality Markers to Look For
The most consistent path to quality CJC-1295 is community research first — peptide forums aggregate real purchasing experience that are more accurate than commercial vendor claims. A COA for CJC-1295 should include: HPLC purity percentage with the underlying chromatogram, mass spectrometry data verifying the correct molecular weight, endotoxin test results, and a residual solvent panel — all traceable to your batch. For Aígio researchers evaluating unfamiliar vendors: a modest first purchase to test the product before placing larger orders is the accepted approach among experienced researchers. For Aígio researchers making a first CJC-1295 purchase: work through this evaluation framework first, start with a modest quantity, and check that batch numbers on your vial match the COA before use.
Order CJC-1295 — ships to Aígio
COA-verified · International tracking · Research grade
CJC-1295 is available for research use only and is not approved for human therapeutic use by the FDA or equivalent agencies worldwide — all information here is provided for educational purposes. Storage requirements for CJC-1295: lyophilised powder at minus 20°C, reconstituted solution stored refrigerated at 2-8°C and used within 30 days; reconstitute only with sterile bacteriostatic water. Quality CJC-1295 sourcing is not separable from research safety — bacterial endotoxin contamination, mislabeling, and degradation products are all safety issues that proper COA verification addresses. PubMed and bioRxiv are the primary literature resources for CJC-1295 research; focus on peer-reviewed publications with documented compound quality over unreviewed preprints or forum reports.
Frequently Asked Questions
What is the difference between CJC-1295 with DAC and without DAC?
CJC-1295 with DAC uses a lysine-maleimide conjugate to bind covalently to albumin in the bloodstream, extending half-life to ~6-8 days and creating sustained GH elevation. CJC-1295 without DAC (also called Mod GRF 1-29) has a half-life of ~30 minutes and produces acute GH pulses. They produce different GH secretion patterns and have different applications in research.
What purity is required for CJC-1295 research?
CJC-1295 should be ≥98% pure by HPLC. The larger molecular weight of CJC-1295 with DAC (approximately 3647 Da) makes mass spectrometry confirmation particularly important, as impurities may not be obvious on HPLC alone.
What is CJC-1295?
CJC-1295 is a synthetic GHRH (Growth Hormone Releasing Hormone) analogue. The version with DAC (Drug Affinity Complex) has an extended half-life of approximately 6-8 days due to albumin binding. Without DAC, CJC-1295 has a much shorter half-life similar to native GHRH. Both versions stimulate pulsatile GH release via the GHRH receptor.
